SOUTH SAN FRANCISCO, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today reported financial results for the second quarter 2016, and reviewed recent corporate and clinical development progress.
"We had a highly productive second quarter and remain on track to complete enrollment in both the EPIC and CARE studies in 2016 and to report top-line results from both studies as planned in 2017,” said Kenneth Hillan, M.B. Ch.B., Achaogen's Chief Executive Officer. “In addition, we successfully secured additional capital resources and funding awards to advance plazomicin through top-line data."
"We had a highly productive second quarter and remain on track to complete enrollment in both the EPIC and CARE studies in 2016 and to report top-line results from both studies as planned in 2017,” said Kenneth Hillan, M.B. Ch.B., Achaogen's Chief Executive Officer. “In addition, we successfully secured additional capital resources and funding awards to advance plazomicin through top-line data."
